In patients with AML with FMS-like tyrosine kinase 3 (FLT3) mutations, the significance of minimal residual disease (MRD) detected by PCR before allogeneic stem cell transplantation (SCT) on outcomes after transplant remains unclear. We identified 200 patients with FLT3-AML who underwent SCT at our institution. Disease status at transplant was: first or second complete remission (CR1/CR2, n 5 119), high-risk CR (third or subsequent CR, marrow hypoplasia, or incomplete count recovery) (CR-HR, n 5 31), and morphological evidence of active disease (AD, n 5 50). The median follow-up was 27 months, and the 2-year overall and progression-free survival were 43% and 41%, respectively. Relapse was highest in the AD group (85%) and the CR-HR FLT3 MRD positive group (72%), followed by CR-HR FLT3 MRD negative (58%), CR1/CR2 FLT3 MRD positive (39%), and lowest in the CR1/CR2 FLT3 MRD negative group (23%). On multivariate analysis, independent factors influencing the risk of relapse were detectable morphological disease and FLT3 MRD by PCR pre-transplant. Factors that did not influence the relapse risk included: age, graft type, graft source, type of FLT3 mutation, or conditioning intensity. Morphologic and molecular remission status at the time of transplant were key predictors of disease relapse and survival in patients with FLT3-AML. 
| I N T R O D U C T I O N
In acute myeloid leukemia (AML), cytogenetic abnormalities strongly influence treatment outcomes. However, the role of molecular abnormalities remains less well understood. Acquired somatic mutations in the FMS-related tyrosine kinase 3 (FLT3) gene are present in up to 30% of patients with AML with diploid cytogenetics, which makes these patients. [6] [7] [8] [9] Even after SCT, disease relapse remains a significant cause of treatment failure. 5, 10 Some studies identified the presence of a high ratio of mutant to wild-type FLT3 alleles as a high-risk feature in patients with FLT3 mutated AML. 11 However, in patients with FLT3-mutated AML treated with SCT other potential predictors of a relapse remain incompletely understood.
Minimal residual disease (MRD) detection techniques are emerging
as useful tools to risk stratify patients both before and after SCT. 12 Many centers now use multicolor flow cytometry for MRD detection in AML patients. The use of polymerase chain reaction (PCR) for detection of MRD is still controversial, and most centers do not routinely use PCR for MRD detection. 13, 14 Moreover, the utility of FLT3 detection by PCR as a minimal residual disease marker at the time of SCT and its impact on post-transplant relapse rates is unknown.
The aim of this study was to assess the impact of disease status before transplant on relapse and survival in patients with FLT3 mutated AML treated with SCT. Specifically, we investigated the utility of MRD detection by PCR pre-transplant on the prognosis of these patients.
| M E T H O D S

| Study design and data collection
We retrospectively screened 1255 AML patients who underwent their first SCT between January 2000 and October 2014 and identified 200 adult patients with FLT3 ITD or FLT3 TKD mutations detected at diagnosis (Table 1) . Patients were considered to have FLT3 mutated AML if one of these mutation types was detected, irrespective of the allele burden.
FLT3 status before transplant was assessed using bone marrow samples collected within 30 days before the patient received the transplant.
| F L T MUTATION DET ECT ION
A multiplex fluorescence-based PCR analysis for ITD and kinase domain (D835, D836) mutations in FLT3 was performed on DNA isolated from bone marrow aspirate samples as previously described. 15 Briefly, fluorescently labeled PCR primers were used to amplify targeted juxtamembrane domain and kinase domain sequences. PCR product sizes were determined using capillary gel electrophoresis on a 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA). The presence of PCR fragments larger than the wild-type allele indicated ITD.
To detect TKD D835/D836 mutation, PCR products were digested with the EcoRV restriction enzyme before capillary electrophoresis.
Wild-type alleles cut by this enzyme yield two fragments, whereas alleles with mutations at D835/D836, which alter the EcoRV recognition site, yield one fragment. The analytical sensitivity of these assays is approximately 1% mutant alleles in a background of wild-type alleles.
| D E FI N I T I O NS AN D E ND P O I NT S
The main objective was to study the impact of MRD detected by PCR (done on marrow samples within 30 days preceding the SCT) on risk of relapse post-transplant in patients with FLT3 mutated AML. The primary endpoint was to determine the effect of FLT3 PCR detected prior to transplant on relapse incidence appreciated by the 2-year cumulative incidence of relapse. The secondary endpoints were the 2-year non-relapse mortality (NRM), overall survival, and progression-free survival (PFS). On morphologic examination, presence of disease was defined as more than 5% blasts in the bone marrow.
Outcomes were compared between subgroups according to their 
| Statistical methods
Time to event was assessed from the day of stem cell infusion. Overall survival and PFS were estimated by the Kaplan-Meier method. For overall survival, death from any cause was considered an event, while for PFS, death or disease relapse was considered an event. The risk of relapse was estimated using the cumulative incidence method, with death in the absence of disease considered a competing risk. 16 Risk factors for disease progression and PFS were assessed on univariate and multivariate analysis using Cox proportional hazards regression analysis. Statistical significance was defined at the 0.05 level. Analyses were performed using Stata 11 (StataCorp LP, College Station, TX).
| R E S U L T S 5.1 | Patient characteristics
Patient characteristics are summarized in Table 1 . The median age was 51 years (range 18-72 years). Eighty-five percent of patients received myeloablative conditioning (n 5 170). At the time of transplant, by morphologic examination, 49% of patients (n 5 99) were in CR1, 10% (n 5 20)
were in CR2, 16% (n 5 31) were in CR-HR, and 25% had morphologic detectable disease (more than 5% bone marrow blasts) (AD; n 5 50).
Patients with high-risk morphological remission (N 5 31, 16%) included:
CR3 or subsequent CR (n 5 4), CRi or marrow hypoplasia after PIF (n 5 13), and CRi or marrow hypoplasia after 1st relapse (n5 14). Of the 150 patients in CR1, CR2, or CR-HR, 27 patients had detectable FLT3 by PCR (CR1 or CR2, n 5 11; CR-HR, n 5 16). Eighty-four percent of patients had FLT3 ITD, while 17% of patients had FLT3 TKD mutations. reduced-intensity) ( Table 2) . On multivariate analysis, the only two independent factors associated with a higher risk of disease relapse were detectable disease by morphological examination and molecular detection of FLT3 MRD by PCR at the time of transplant (Table 2 ).
| Impact of FLT3 by PCR on relapse
| Non-relapse mortality
Compared to patients in CR1, NRM was higher in patients in CR2 (haz- On multivariate analysis, KPS 80% (HR 4, P 5 0.001) and patients not in CR with detectable FLT3 by PCR at transplant (HR 3.6, P 5 0.001)
were independently associated with a higher risk of NRM (HR 5.1,
The causes of NRM in this cohort were graft-versus-host disease (n 5 10, 9%), infection (n 5 9, 8%), regimen-related toxicity (n 5 8, 7%), graft failure (n 5 1, 1%), and other causes (n 5 7, 6%).
| Survival
The median follow-up among survivors was 27 months (range 3-139 months), and the 2-year overall survival and PFS rates for the entire group were 43% and 41%, respectively ( Figure 2) . One hundred ten patients died, and leukemia relapse was the most common cause of death (n 5 75, 68% of deaths).
Morphologic and molecular disease status at the time of transplant were significantly associated with PFS. PFS was not significantly worse for patients in CR2 than in patients in CR1 (HR 1.5, P 5 0.3); however, PFS was lower in patients in CR-HR (HR 3.9, P < 0.001) and patients with disease detected by morphologic analysis (HR 5.9, P < 0.001) than in patients in CR1 ( Table 2 ). The Table 2) . No significant association was identified between PFS and age above 50 years, conditioning intensity, or stem cell source (peripheral blood vs. bone marrow).
| DISCUSSION
We investigated the role of mutated FLT3 detected by PCR as an MRD marker, evaluated immediately before transplant, on transplant outcomes in patients with FLT3-AML undergoing SCT, and found that disease status before transplant measured not only morphologically but also molecularly independently influenced the risk of leukemia relapse and survival after transplant in these patients. Detection of mutated FLT3 by PCR before transplant was associated with higher relapse risk and worse survival in all pre-transplant morphologic disease status groups, suggesting that detecting FLT3 by PCR is a useful tool to better assess MRD prior to transplant and stratifies these patients by relapse risk more effectively than morphologic examination alone.
In general, the risk of disease relapse post-transplant is highest among patients with evidence of residual disease assessed by morphologic analysis at the time of transplant. 17 In our study, the depth of remission, assessed morphologically and molecularly, shortly before transplant was significantly associated with the risk of leukemia relapse after transplant. Patients with evidence of morphologic disease present at the time of transplant had the highest risk of relapse (85%), followed by patients in CR-HR, while patients in CR1 or CR2 at the time of transplant had the lowest risk of relapse rate, as predicted. Similarly, molecular disease status before transplant, represented by mutated FLT3 detected by conventional PCR, was a useful MRD marker, as this measure further stratified patients by risk of relapse. Patients in CR1 or CR2 with FLT3 MRD negative disease by PCR at the time of transplant had the lowest incidence of relapse after transplant (23%) and excellent survival, suggesting a beneficial effect of SCT for these patients. Similarly, the molecular remission status was useful in patients with CR-HR.
In this group, patients with detectable FLT3 MRD by PCR before transplant had a very high incidence of leukemic relapse (72%), similar to that in patients with morphologic evidence of disease (>5% blasts) before transplant. cytometry (routinely available after 2012). However, this is the largest study of patients with FLT3-mutated AML undergoing allogeneic stem cell transplantation to date and the first to detect a significant impact of MRD detected by PCR for the FLT3 mutations immediately pretransplant, as well as an impact of disease detected by morphologic analysis, on relapse and survival. Ultimately, these findings will need to be confirmed in prospective trials.
In conclusion, in patients with FLT3-mutated AML, the degree of disease control, not only morphologically but also molecularly shortly before transplant is an influential factor predicting disease relapse post-transplant. By testing for FLT3 mutations by PCR pre-transplant, as a MRD marker, we were able to further risk stratify disease relapse 
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